Report period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
ABBV:US | AbbVie Inc. | Common share | - | US00287Y1091 | $166.4 |
Company name | AbbVie |
---|---|
Tags | #pharmacy, #dividend aristocrats, #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
Business address | 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900 |
Mailing address | 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 |
Website | investors.abbvie.com |
Information disclosure | www.sec.gov |